| Popis: |
BACKGROUND In recent years, with the scientific and technological progress, new drugs for breast cancer have been developed constantly, and the OS and DFS of breast cancer patients are also improving. However, the large number of drugs has also made the clinical trials of drugs disordered. OBJECTIVE To overcome the existing problems in targeted therapy and figure out the best choice of targeted therapy. METHODS we proposed the method of permutation and combination to classify the drugs for Her-2 targeted therapy, and analyzed the most common drugs (mainly the drugs recommended by NCCN) through single comparison, single-double comparison and pairwise comparison, and analyzed the related neoadjuvant/ adjuvant chemotherapy, early / advanced breast cancer, first / second line clinical trials, so as to systematically summarize the previous clinical data on targeted therapy. RESULTS In single comparison, tratuzumab is still strong, while T-DM1 is developing. In single double comparison, T+P is strong and T-DM1+L will be promising in the short term, more combination therapy included ADC and targeted drugs are potential to be developed. Meanwhile, TKI and ADC for BCBM and more newly developed ADC are presence of new drug trials. What's more, the ADC drugs is developed targeted more. CONCLUSIONS We point out the research direction and potential breakthrough of targeted therapy in the future, hoping to provide the most direct help to the clinical practice. |
